Sellas Life Sciences is trading 10.22% down at $13.65 as investors reverse recent enthusiasm surrounding the REGAL leukemia trial.
- No fresh company-specific announcement was identified for August 28, 2026; the latest confirmed corporate update dates to August 11.
- Biotech stocks are down 2.31% as investors react defensively to hawkish Federal Reserve signals and higher-rate concerns.